Article Text

Download PDFPDF
Primary intestinal autoimmune disease as a cause of chronic intestinal pseudo-obstruction
  1. S Ghirardo1,*,
  2. B Sauter1,*,
  3. G Levy2,
  4. I M Fiel2,
  5. T Schiano3,
  6. G Gondolesi3
  1. 1Intestinal Rehabilitation and Transplantation, Recanati Miller Transplantation Institute, The Mount Sinai Medical Center, New York, USA
  2. 2Department of Pathology, The Mount Sinai Medical Center, New York, USA
  3. 3Intestinal Rehabilitation and Transplantation, Recanati Miller Transplantation Institute, The Mount Sinai Medical Center, New York, USA
  1. Correspondence to:
    G Gondelesi
    Surgical Director of Intestinal Rehabilitation and Transplantation, The Mount Sinai Medical Center, One Gustave L Levy Place, Box 1104, New York, NY 10029-6574, USA; gabriel.gondolesimsnyuhealth.org

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

The purpose of this letter is to elucidate on the pathophysiology of a disease that is often considered to be idiopathic. Chronic intestinal pseudo-obstruction (CIPO) is a clinical syndrome characterised by ineffective intestinal propulsion in the absence of organic intestinal obstruction. It is a common cause of intestinal failure requiring total parenteral nutrition (TPN). It can be either a primary/idiopathic (neurogenic or myogenic) disorder or secondary to another recognised underlying disease. Most cases of childhood CIPO are congenital enteral neuromuscular diseases; however, neuropathy due to Hirschprung’s disease, Chagas disease, infections, and toxins occur in later childhood. In adults, most cases of CIPO are secondary to progressive systemic sclerosis, dermatomyositis, systemic lupus erythematosus, rheumatoid arthritis, and Sjogren’s syndrome.1,2

We report a case of an adult onset of CIPO secondary to an autoimmune process affecting exclusively …

View Full Text